Skip to main content

Advertisement

SpringerLink
Log in

Endothelin-1, α-Klotho, 25(OH) Vit D levels and severity of disease in scleroderma patients

  • Biomarkers
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Considering the role of endothelin-1 (ET-1) in tissue remodeling and fibrosis during the development of scleroderma as well as the effect of α-Klotho in pathogenesis of calcinosis and/or endothelial cell injury and its correlation with severity of disease, this study aimed to evaluate serum ET-1, α-Klotho and 25(OH) vitamin D levels in patients with limited and diffuse scleroderma compared to healthy subjects. In this cross-sectional study, 60 scleroderma patients according to the ACR/EULAR 2013 criteria and 60 age- and sex-matched healthy controls were included. In patients, clinical examination was performed and Medsger severity scale was assessed. Serum ET-1, soluble α-Klotho and 25(OH)D3 levels were measured using ELISA kits. The mean ± SD age of patients and controls was 46.2 ± 9.6 and 47.2 ± 7.0 years, respectively. Compared to healthy controls, serum ET-1 was significantly higher in SSc patients (p = 0.001); whilst serum α-Klotho and 25(OH)D3 were significantly lower in patients (p = 0.001). The most common organs involved in patients were skin, lung, peripheral vascular and gastrointestinal system and the severity of involvement was mainly mild and/or moderate. There were no significant differences in serum ET-1 and α-Klotho levels according to the severity of different organ involvement (p > 0.05). There was no significant correlation between presence or absence of calcinosis and negative or positivity of auto-antibodies with ET-1, α-Klotho and 25(OH)D3 levels. Although our study revealed higher serum ET-1 and lower serum α-Klotho levels in SSc patients compared to healthy controls, there were not any significant correlations between their serum levels with severity of organ involvement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Aghaei M, Gharibdost F, Zayeni H, Akhlaghi M, Sedighi Sima, Rostamian AR et al (2012) Endothelin-1 in systemic sclerosis. Indian Dermatol Online J 3(1):14–16

    Article  PubMed  PubMed Central  Google Scholar 

  2. Shiwen X, Leask A, Abraham DJ, Fonseca C (2009) Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma. Eur J Clin Invest 39(Suppl 2):19–26

    Article  CAS  PubMed  Google Scholar 

  3. Hachulla E, Launay D (2011) Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol 40(2):78–83

    Article  PubMed  Google Scholar 

  4. Valentini G (2002) Sistematic sclerosis. Best Pract Res Clin Rheumatol 16(5):807–816

    Article  PubMed  Google Scholar 

  5. Shi-Wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD et al (2001) Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 116(3):417–425

    Article  CAS  PubMed  Google Scholar 

  6. Goldie RG, Knott PG, Carr MJ, Hay DW, Henry PJ (1996) The endothelins in the pulmonary system. Pulm Pharmacol 9(2):69–93

    Article  CAS  PubMed  Google Scholar 

  7. Davenport AP, Maguire JJ (2006) Endothelin. Handb Exp Pharmacol 176/I:295–329

    Article  Google Scholar 

  8. Morris E, Chrobak I, Bujor A, Hant F, Mummery C, Ten Dijke P et al (2011) Endoglin promotes TGFbeta/Smad1 signaling in scleroderma fibroblasts. J Cell Physiol 226(12):3340–3348

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Yamane K, Kashiwagi H, Suzuki N, Miyauchi T, Yanagisawa M, Goto K et al (1991) Elevated plasma levels of endothelin-1 in systemic sclerosis. Arthritis Rheum 34(2):243–244

    Article  CAS  PubMed  Google Scholar 

  10. Kahaleh MB (1991) Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 34(8):978–983

    Article  CAS  PubMed  Google Scholar 

  11. Cozzani E, Javor S, Laborai E, Drosera M, Parodi A (2013) Endothelin-1 levels in scleroderma patients: a pilot study. ISRN Dermatol 2013:1–5

    Article  Google Scholar 

  12. Kim HS, Park MK, Kim HY, Park SH (2010) Capillary dimension measured by computer-based digitalized image correlated with plasma endothelin-1 levels in patients with systemic sclerosis. Clin Rheumatol 29(3):247–254

    Article  PubMed  Google Scholar 

  13. Sulli A, Soldano S, Pizzorni C, Montagna P, Secchi ME, Villaggio B et al (2009) Raynaud’s phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis. J Rheumatol 36(6):1235–1239

    Article  CAS  PubMed  Google Scholar 

  14. Nakano D, Pollock D (2012) New concepts in endothelin control of sodium balance. Clin Exp Pharmacol Physiol 39(1):104–110

    Article  CAS  PubMed  Google Scholar 

  15. Wang Y, Sun Z (2014) Antiaging gene Klotho regulates endothelin-1 levels and endothelin receptor subtype B expression in kidneys of spontaneously hypertensive rats. J Hypertens 32(8):1629–1636

    Article  CAS  PubMed  Google Scholar 

  16. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T et al (1997) Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature 390(6655):45–51

    Article  CAS  PubMed  Google Scholar 

  17. Kuro-o M (2010) Klotho. Pflugers Arch 459(2):333–343

    Article  CAS  PubMed  Google Scholar 

  18. Talotta R, Atzeni F, Bongiovanni S, Ditto MC, Letizia T, Vago T et al (2016) Measurement of serum alpha-Klotho in systemic sclerosis patients: results from a pivotal study. Sci Abstracts AB0635:1121

    Google Scholar 

  19. Martin-Nunez E, Donate-Correa J, Muros-de-Fuentes M, Mora-Fernandez C, Navarro-Gonzalez JF (2014) Implications of Klotho in vascular health and disease. World J Cardiol 6(12):1262–1269

    Article  PubMed  PubMed Central  Google Scholar 

  20. Mazzotta C, Manetti M, Rosa I, Romano E, Blagojevic J, Bellando-Randone S et al (2017) Proangiogenic effects of soluble α-Klotho on systemic sclerosis dermal microvascular endothelial cells. ‎Arthritis Res Ther 19:27–40

    Article  PubMed  PubMed Central  Google Scholar 

  21. Haussler MR, Whitfield GK, Kaneko I, Forster R, Saini R, Hsieh JC et al (2012) The role of vitamin D in the FGF23, Klotho, and phosphate bone-kidney endocrine axis. Rev Endocr Metab Disord 13(1):57–69

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Haussler MR, Haussler CA, Whitfield GK, Hsieh JC, Thompson PD, Barthel TK (2010) The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the “Fountain of Youth” to mediate healthful aging. J Steroid Biochem Mol Biol 121(1–2):88–97

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Corrado A, Colia R, Mele A, Di Bello V, Trotta A, Neve A et al (2015) Relationship between body mass composition, bone mineral density, skin fibrosis and 25(OH) vitamin D serum levels in systemic sclerosis. PLoS One 10(9):e0137912–e0137924

    Article  PubMed  PubMed Central  Google Scholar 

  24. Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum 65(11):2737–2747

    Article  PubMed  PubMed Central  Google Scholar 

  25. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W (2003) Assessment of disease severity and prognosis. Clin Exp Rheumatol 21(3 Suppl 29):42–46

    Google Scholar 

  26. Mulligan-Kehoe MJ, Simons M (2008) Vascular disease in scleroderma: angiogenesis and vascular repair. Rheum Dis Clin North Am 34(1):73–79

    Article  PubMed  Google Scholar 

  27. Bassyouni IH, Gheita TA, Talaat RM (2011) Clinical significance of serum levels of sCD36 in patients with systemic sclerosis: preliminary data. Rheumatology (Oxford) 50(11):2108–2112

    Article  CAS  Google Scholar 

  28. Scardina GA, Mazzullo M, Messina P (2002) Early diagnosis of progressive systemic sclerosis: the role of oro-facia phenomena. Minerva Stomatol 51(7–8):311–318

    CAS  PubMed  Google Scholar 

  29. Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P, Shi-wen X et al (1997) Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 151(3):831–834

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E et al (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50(12):3985–3993

    Article  CAS  PubMed  Google Scholar 

  31. Peterlana D, Puccetti A, Caramaschi P, Biasi D, Beri R, Simeoni S et al (2006) Endothelin-1 serum levels correlate with MCP-1 but not with homocysteine plasma concentration in patients with systemic sclerosis. Scand J Rheumatol 35(2):133–137

    Article  CAS  PubMed  Google Scholar 

  32. Morelli S, Ferri C, Francesco LD, Baldoncini R, Carlesimo M, Bottoni U et al (1995) Plasma endothelin-1 levels in patients with systemic sclerosis: Influence of pulmonary or systemic arterial hypertension. Ann Rheum Dis 54(9):730–734

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Morelli S, Ferri C, Polettini E, Bellini C, Gualdi GF, Pittoni V et al (1995) Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med 99(3):255–260

    Article  CAS  PubMed  Google Scholar 

  34. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, Black CM (1994) Circulating endothelin-1 levels in systemic sclerosis subsets—a marker of fibrosis or vascular dysfunction? J Rheumatol 21(10):1838–1844

    CAS  PubMed  Google Scholar 

  35. Jing J, Dou TT, Yang JQ, Chen XB, Cao HL, Min M et al (2015) Role of endothelin-1 in the skin fibrosis of systemic sclerosis. Eur Cytokine Netw 26(1):10–14

    CAS  PubMed  Google Scholar 

  36. Pedersen L, Pedersen SM, Brasen CL, Rasmussen LM (2013) Soluble serum Klotho levels in healthy subjects. Comparison of two different immunoassays. Clin Biochem 46(12):1079–1083

    Article  CAS  PubMed  Google Scholar 

  37. Akimoto T, Morishita Y, Ito C, Iimura O, Tsunematsu S, Watanabe Y et al (2014) Febuxostat for hyperuricemia in patients with advanced chronic kidney disease. Drug Target Insights 8:39–43

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408(6809):239–247

    Article  CAS  PubMed  Google Scholar 

  39. Saito Y, Yamagishi T, Nakamura T, Ohyama Y, Aizawa H, Suga T et al (1998) Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun 248(2):324–329

    Article  CAS  PubMed  Google Scholar 

  40. Saito Y, Nakamura T, Ohyama Y, Suzuki T, Iida A, Shiraki-Iida T et al (2000) In vivo Klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome. Biochem Biophys Res Commun 276(2):767–772

    Article  CAS  PubMed  Google Scholar 

  41. Liu F, Wu S, Ren H, Gu J (2011) Klotho suppresses RIG-I-mediated senescence-associated inflammation. Nat Cell Biol 13(3):254–262

    Article  CAS  PubMed  Google Scholar 

  42. Zhao Y, Banerjee S, Dey N, LeJeune WS, Sarkar PS, Brobey R et al (2011) Klotho depletion contributes to increased inflammation in kidney of the db/dbmouse model of diabetes via RelA (serine)536 phosphorylation. Diabetes 60(7):1907–1916

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Yamazaki Y, Imura A, Urakawa I, Shimada T, Murakami J, Aono Y et al (2010) Establishment of sandwich ELISA for soluble alpha-Klotho measurement: age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun 398(3):513–518

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Siahanidou T, Garatzioti M, Lazaropoulou C, Kourlaba G, Papassotiriou I, Kino T et al (2012) Plasma soluble alpha-Klotho protein levels in premature and term neonates: correlations with growth and metabolic parameters. Eur J Endocrinol 167(3):433–440

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Hu MC, Shi M, Zhang J, Quiñones H, Griffith C, Kuro-o M et al (2011) Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Society Nephrol 22(1):124–136

    Article  CAS  Google Scholar 

  46. Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K et al (2010) Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77(3):232–238

    Article  CAS  PubMed  Google Scholar 

  47. Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, Nakatani T et al (2001) Severely reduced production of Klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 280(4):1015–1020

    Article  CAS  PubMed  Google Scholar 

  48. Kitagawa M, Sugiyama H, Morinaga H, Inoue T, Takiue K, Ogawa A et al (2013) A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PLoS One 8(2):1–10

    Article  Google Scholar 

  49. Kim HR, Nam BY, Kim DW, Kang MW, Han JH, Lee MJ et al (2013) Circulating alpha Klotho levels in CKD and relationship to progression. Am J Kidney Dis 61(6):899–909

    Article  CAS  PubMed  Google Scholar 

  50. Ushigusa T, Ichinose K, Sato S, Michitsuji T, Shimizu T, Umeda M et al (2016) Soluble α-Klotho is a potential biomarker associated with neuropsychiatric systemic lupus erythematosus. Clin Immunol 165:29–34

    Article  CAS  PubMed  Google Scholar 

  51. Belloli L, Ughi N, Marasini B (2011) Vitamin D in systemic sclerosis. Clin Rheumatol 30:145–146

    Article  PubMed  Google Scholar 

  52. Caramaschi P, Dalla Gassa A, Ruzzenente O, Volpe A, Ravagnani V, Tinazzi I (2010) Very low levels of vitamin D in systemic sclerosis patients. Clin Rhematol 29(12):1419–1425

    Article  Google Scholar 

  53. Braun-Moscovici Y, Furst DE, Markovits D, Rozin A, Clements PJ, Nahir AM et al (2008) Vitamin D, parathyroid hormone and acroosteolysis in SSc. J Rheumatol 35(11):2201–2205

    Article  CAS  PubMed  Google Scholar 

  54. Calzolari G, Data V, Carignola R, Angeli A (2009) Hypovitaminosis D in sistemic sclerosis. J Rheumatol 36(12):2844

    Article  PubMed  Google Scholar 

  55. Arnson Y, Amital H, Agmon-Levin N, Alon D, Sánchez-Castañón M, López-Hoyos M et al (2011) Serum 25OH vitamin D concentrations are linked with various clinical aspects in patients with SSc: a retrospective cohort study and review of literature. Autoimmun Rev 10(8):490–494

    Article  CAS  PubMed  Google Scholar 

  56. Rios Fernandez R, Roldan CF, Callejas Rubio JL, Centeno N (2010) Vitamin D deficiency in a cohort of patients with systemic scleroderma from S of Spain. J Rheumatol 37(6):1355

    Article  PubMed  Google Scholar 

  57. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB et al (2013) Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev 12(10):976–989

    Article  CAS  PubMed  Google Scholar 

  58. Ahmadi R, Hajialilo M, Ghorbanihaghjo A, Mota A, Raeisi S, Bargahi N et al (2017) FGF-23, Klotho and vitamin D levels in scleroderma. Iran J Public Health 46(4):530–536

    PubMed  PubMed Central  Google Scholar 

  59. Groseanu L, Bojinca V, Gudu T, Saulescu I, Predeteanu D, Balanescu A et al (2016) Low vitamin D status in systemic sclerosis and the impact on disease phenotype. Eur J Rheumatol 3(2):50–55

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The authors wish to thank all the subjects for their participation in this research.

Author information

Authors and Affiliations

  1. Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    Mehrzad Hajialilo, Parisa Noorabadi, Sepideh Tahsini Tekantapeh & Aida Malek Mahdavi

Authors
  1. Mehrzad Hajialilo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Parisa Noorabadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sepideh Tahsini Tekantapeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aida Malek Mahdavi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aida Malek Mahdavi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

This research was funded by the Connective Tissue Diseases Research Center of Tabriz University of Medical Sciences.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standard.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hajialilo, M., Noorabadi, P., Tahsini Tekantapeh, S. et al. Endothelin-1, α-Klotho, 25(OH) Vit D levels and severity of disease in scleroderma patients. Rheumatol Int 37, 1651–1657 (2017). https://doi.org/10.1007/s00296-017-3797-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-017-3797-z

Keywords

Search

Navigation